| Name | Ergomed |
|---|---|
| Epic | ERGO |
| Isin | GB00BN7ZCY67 |
| Index | AIM50 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,346.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £701.04 | Debt ratio | n/a |
| Shares in issue | 50.81 | Debt-to-equity ratio | n/a |
| P/E ratio | 29.9 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 54.79 |
| Dividend cover | n/a | EPS growth | 4 |
| Earning per share | 30.1 | 52-week high / low | 910.00p / 1,380.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Ergomed |
|---|---|
| Address | 1 Occam Court, Surrey Research Park, Guildford, Surrey, United Kingdom, GU2 7HJ |
| Telephone | |
| Website | http://ergomedplc.com/ |
| Director | Position |
|---|---|
| Mr Jonathan Curtain | CFO |
| Dr Miroslav Reljanovic | Executive Chairman |
| Mr John Dawson | Senior Independent Director |
| Dr Llew Keltner | Independent Non-Executive Director |
| Ms Anne Whitaker | Independent Non-Executive Director |
| Mr Mark Enyedy | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 57.25 | 31.56 | 34.22 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 71.11 | 45.65 | 45.58 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 34.45 | 25.14 | 22.22 |
| Cash and equivalents | 19.1 | 31.24 | 18.99 |
| Other current assets and asset held for resale | 4.7 | 3.96 | 5.55 |
| Total of all assets | 129.35 | 105.99 | 92.35 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 38.89 | 35.38 | 33.61 |
| Long term liabilities | 5.71 | 3.37 | 5.87 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 44.6 | 38.75 | 39.48 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 84.75 | 67.24 | 52.87 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.5 | 0.49 | 0.49 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 72.12 | 59.06 | 45.37 |
| Share premium account | 1.01 | 0.55 | n/a |
| Total equity | 84.75 | 67.24 | 52.87 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 18.87 | 14.62 | 13.53 |
| Pre-tax profit | 17.95 | 14.26 | 12.63 |